Move over, oncology: Obesity, diabetes meds will take over 2030’s top drug rankings …
Reflecting a new shift, oncology drugs have taken a back seat to the rise of obesity and diabetes meds, specifically from Novo Nordisk and Eli Lilly.
Reflecting a new shift, oncology drugs have taken a back seat to the rise of obesity and diabetes meds, specifically from Novo Nordisk and Eli Lilly.
